RCM
FBRX icon

Requisite Capital Management’s Forte Biosciences FBRX Stock Holding History

Requisite Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21
Closed -$31K – 132
2019
Q1 		$31K Buy
+21
New +$81.1K 0.01% 133

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Requisite Capital Management's FBRX Position: Q3 2019 in Review

Requisite Capital Management sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 32 shares — an estimated $80K sold.

Requisite Capital Management first reported a position in FBRX in Q4 2018 and held it in 3 quarters. The position peaked at $566K in Q1 2019. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Requisite Capital Management reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Requisite Capital Management sold 32 Forte Biosciences shares in Q3 2019, an estimated $80K.
  • Requisite Capital Management first reported a position in Forte Biosciences in Q4 2018 and held it in 3 quarters.
  • Requisite Capital Management's Forte Biosciences position peaked at $566K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Requisite Capital Management's 13F filing for Q3 2019, filed 29 Oct 2019.